Latest Capital Raise News

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

Alice Queen Limited has contracted a versatile drilling rig to kickstart a multi-phase exploration program at its Horn Island Gold Project, with operations set to begin mid to late July 2026.

RLF AgTech has revamped its executive remuneration to tie CEO incentives directly to share price hurdles, revenue growth, and operating cash flow, reinforcing its focus on sustainable profitability.

INOVIQ Limited confirms no undisclosed price-sensitive information amid recent share price surge, attributing the move to external research spotlighting upcoming EXO-OC ovarian cancer test data.

Bass Oil has secured full ownership of the Vanessa gas field in the Cooper Basin, aiming to resume gas sales by year-end after recommissioning the facility and pipeline.

Perpetual Resources (ASX: PEC) has locked in a 100% stake in the historic Nevada Scheelite tungsten mine, boasting an average grade of 1.1% WO3 and existing underground infrastructure. The acquisition is backed by a $2.5 million placement to fund validation and exploration.

Novonix has secured A$20.7 million from an institutional placement at a 33% discount, alongside a A$3 million Share Purchase Plan for existing shareholders, aiming to fund production capacity expansion amid growing battery demand.

St George Mining has raised A$60 million through a two-tranche placement led by major shareholder Hancock Prospecting to accelerate development of its high-grade Araxá rare earths and niobium project in Brazil.

Stealth Group Holdings has posted record preliminary FY26 results, driven by strong organic growth and the transformative acquisition of Hardware & Building Traders (HBT). The company remains on track for its ambitious FY28 sales and EBITDA margin targets.

Bounty Oil & Gas has finalised the first tranche of a $4 million share placement and converted $200,000 of debt into shares, bolstering its capital for drilling and development across Australian oil and gas projects.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Hydrix Limited has secured $5.22 million from its retail entitlement offer, leaving nearly $3 million in entitlements unsold, which will be offered separately under a shortfall offer managed by Peak Asset Management.